
Opinion|Videos|April 18, 2024
Exploration into the Management of the Three Symptom Domains of Schizophrenia
Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, provide clinical insights on the treatment of the three symptom domains of schizophrenia, highlighting their manifestations and treatments, including iclepertin.
Advertisement
Episodes in this series

Advertisement
Related to this article

Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.

RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.

Discover how integrated psychotherapy—CBTp, family support, and relapse plans—boosts schizophrenia recovery alongside antipsychotics.

A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Treating PTSD Among Veterans at Risk for Suicide
2
FDA Grants Breakthrough Device Designation to NET Recovery's Device for Stimulant Use Disorder
3
Podcast: Not Always Panic. A Cardiologist and Psychiatrist on Reading a Racing Heart
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5

